Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Deferred Investment Award Programme.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
On January 7, 2013, the Administrators of the Deferred Investment Award Programme notified the Company of increases in notional interests in Ordinary Shares for specific individuals. These increases resulted from the re-investment of dividends paid to shareholders on January 3, 2013, at a price of 1360.25 pence per Share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: January 7, 2013.
- Share Price: 1360.25 pence per Share.
- Event: Re-investment of dividends paid on January 3, 2013.
- Participants: Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Signatory: Victoria Whyte, Company Secretary.